Magellan Rx Pharmacy LLC, Astoria, NY
Is Magellan Rx Pharmacy LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Magellan Rx Pharmacy LLC hold a New York pharmacy license?
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002341 for MAGELLAN RX PHARMACY, Astoria, NY, status INACTIVE, as of Nov 15, 2026.
Has Magellan Rx Pharmacy LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jun 6, 2019), 1 state handoff letter (Jun 6, 2019) and 1 FMD-145 letter (Jun 6, 2019) for Magellan Rx Pharmacy LLC. State board actions: no New York State Education Department action under this exact name and city was found in the New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments (actions dated Jan 14, 1994 to May 19, 2026) on Nov 8, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Magellan Rx Pharmacy LLC
- Location
- Astoria, NY
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jun 6, 2019
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 NAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 3 observations
- State board records
- Not checked (license records); board actions matched: 0
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Magellan Rx Pharmacy LLC, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Jun 6, 2019 | Warning letter close-out | Warning Letter Close Out Issued 06/06/2019 | Not linked by FDA |
| Jun 6, 2019 | FMD-145 letter | FMD-145 Letter Issued 06/06/2019 | FDA copy (archived) |
| Jun 6, 2019 | State handoff letter | State Handoff Letter Issued 06/06/2019 | FDA copy (archived) |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Magellan Rx Pharmacy, LLC, Astoria, NY (FEI number 3012729025), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 9, 2018 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3012729025 | 1066579 |
| Dec 22, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012729025 | 996515 |
Form 483s FDA has published for this site
- Feb 28, 2017: Form 483 to Magellan Rx Pharmacy, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection dated Feb 28, 2017 by FDA (dates on the form not read): 3 observations
- Firm on the cover
- Magellan Rx Pharmacy, LLC, 31-75 23rd Street, Suite 410, Astoria, NY 11106 Producer of Sterile Drug Products THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE . IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION. YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.
- FEI number
- 3012729025
- FDA district office on the cover
- US Food and Drug Administration, ORA, NYK-DO 158-15 Liberty Avenue, Jamaica, NY I 1433, USA Phone: 7 I 8-340-7000
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Inadequate aseptic practices were observed. Specifically,
(A) Personnel were observed donning sterile gloves in the non-classified anteroom.
(B) Personnel failed to disinfect or change gloves frequently enough to prevent contamination between the compounding of each chemotherapy prescription.
(C) Personnel engaged in aseptic processing were observed leaving and re-entering the cleanroom from the non classified anteroom without first replacing gowning apparel.
(D) Personne l were observed using a non-sterile <Redacted B4> inside the ISO 5 <Redacted B4> hood which could come in contact with any sterile components of the IV delivery system.
(E) Personnel were observed touching equipment or other surfaces located outside of the ISO 5 <Redacted B4> hood with g loved hands and then proceeding with aseptic processing without changing or sanitizing gloves.
(F) Failure to remove jewelry, such as earrings, prior to entering the cleanroom according to Policy and Standards# OP.353.03-2015, entitled, "Compounding", effective April 11, 2015. An operator was observed wearing a loop earring in the cleanroom not covered by any gowning apparel or bouffant cap on December 8, 2016.
Observation 2
There is an inadequate facility design and equipment use for sterile operation. Specifically,
(A) The facility design was observed to allow the influx of non-classified quality air from the anteroom into the ISO 7 cleanroom.
(B) A sink is present in the cleanroom located approximately 12 feet away from the ISO 5<Redacted B4> hood .
(C) Failure to operate the ISO 5 <Redacted B4> hood continuously according to Policy and Standards# OP .354.04.1, entitled, "Equipment and Sanitizing", effective July 10, 2014.
A
Observation 3
Your firm fails to have adequate cleaning and disinfecting practices in the aseptic processing areas. Specifically,
(A) Failure to clean ISO 5 <Redacted B4> hoods before its use according to Policy and Standards # OP.354.04-1 , entitled, "Equipment and Sanitization" effective June 10, 2014.
(B) Cleaning wipes used in the ISO 5 <Redacted B4> hoods are not sterile and lint free.
(C) Spori cidal agents are not used in yo ur fac ility's cleanroom and the ISO 5 <Redacted B4> hoods. (D) Equipment, materials, and/or supplies are not disinfected prior to entering the aseptic processing areas.
State board of pharmacy records
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.
What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0002341 | NONRESIDENT PHARMACY | MAGELLAN RX PHARMACY | Astoria, NY | INACTIVE |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- New York State Education Department disciplinary records
- Connecticut Department of Consumer Protection license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.